Erschienen in:
01.02.2007 | Editorial commentary
11C-acetate PET imaging in prostate cancer
verfasst von:
Michael J. Morris, Howard I. Scher
Erschienen in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Ausgabe 2/2007
Einloggen, um Zugang zu erhalten
Excerpt
The patient population with a rising PSA following definitive local therapy represents the second largest group of prostate cancer patients [
1]. These patients are characterized by a rising marker following definitive local therapy with either surgery or radiation, and by definition have no evidence of disease on standard imaging studies [
2]. By some estimates, approximately 50,000 men in the USA enter this clinical state each year [
3]. Although some reports suggest that the median amount of time that a patient will spend in this clinical state before developing metastatic disease is 8 years [
4], in actuality these patients represent a wide spectrum of clinical risk. Some have rapidly progressive micrometastatic disease and are at high risk for developing metastases; others experience locally persistent disease or an otherwise indolent clinical course. …